Skip to content
AnalystLens

Cigna Group 8-K Report, Regulation FD Disclosure (Mar 7, 2024)

Reports
Regulation FD·Exhibits & Filings
Filing Date
Filed March 7, 2024
Period End
March 7, 2024
Security
CI
In the record · 2018–202610-K810-Q238-K136

CI filed 8 annual reports (10-K), 23 quarterly reports (10-Q) and 136 current reports (8-K) between 2018 and 2026.

  1. Deal closed8-K · Feb ’19Feb ’19
  2. Material agreement8-K · Apr ’21Apr ’21
  3. Leadership change8-K · May ’23May ’23
  4. Leadership change8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed March 7, 2024. Cited figures are marked; the original filing is the authoritative source.

The Cigna Group (CI) filed this Form 8-K on March 7, 2024 under Regulation FD to furnish a press release tied to its 2024 Investor Day.

The company reaffirmed its full-year 2024 outlook of consolidated adjusted revenues of at least $235 billiona and adjusted income from operations of at least $28.25 per share, noting that the outlook includes the impact of expected share repurchases and anticipated 2024 dividends. Management expects to reaffirm this guidance during Investor Day and in investor meetings over the following several weeks. No new numerical guidance was introduced, so the outlook is unchanged from the February 2, 2024 release.

The main new item for investors is a raised long-term average annual adjusted EPS growth target of 10%b-14%. This signals management's confidence in multi-year earnings expansion beyond the 2024 outlook, though the filing does not provide the prior target for comparison or detail the drivers behind the increase. Because long-term targets are forward-looking and not tied to a specific reporting period, investors should weigh them against execution risks, including pricing pressure, medical cost trends, and government program exposure, which the filing flags in its forward-looking statements section.

The press release also highlights three product and service initiatives from Evernorth: an EncircleRx financial guarantee for GLP-1 drug costs, a new Evernorth Behavioral Care Group aimed at expanding in-network mental health access, and a planned $0c out-of-pocket Humira biosimilar for eligible Accredo patients. These announcements are strategically relevant to cost containment and pharmacy services, but the filing gives no financial impact estimates for them. The filing also states that the information is furnished rather than filed, so it is not subject to Section 18 liability unless specifically incorporated into another filing.

02—Key points

Key Highlights

  1. Reaffirmed full-year 2024 guidance: consolidated adjusted revenues of at least $235 billion and adjusted income from operations of at least $28.25 per share, including the effects of expected share repurchases and 2024 dividends.
  2. Raised the long-term average annual adjusted EPS growth target to 10%-14%, a key new forward-looking metric presented at Investor Day.
  3. Announced EncircleRx, described as the industry's first financial guarantee for GLP-1 drug costs, offering cost caps or savings guarantees to employers and health plans through Express Scripts by Evernorth.
  4. Launched Evernorth Behavioral Care Group, a behavioral health practice guaranteeing an in-person or virtual appointment within 72 hours of scheduling, with full scale targeted for 2025.
  5. Planned availability of a Humira biosimilar at $0 out-of-pocket cost for eligible Accredo specialty pharmacy patients later in 2024.
  6. Investor Day ran from approximately 8:30 a.m. to 12:30 p.m. ET on March 7, 2024, in New York and virtually, with materials and non-GAAP reconciliations posted to the Investor Relations website.
  7. The filing notes that management cannot provide forward-looking reconciliations of adjusted metrics to GAAP because future realized investment results and special items cannot be predicted without unreasonable effort.

03—Questions

Frequently Asked Questions

  1. Did Cigna change its 2024 earnings guidance at Investor Day?

    No. Cigna reaffirmed its 2024 outlook of at least $235 billion in adjusted revenues and at least $28.25 per share in adjusted income from operations, the same figures given in its February 2, 2024 earnings release. The new item was the long-term growth target, not a change to 2024 guidance.

  2. What is the new long-term growth target?

    Cigna raised its long-term average annual adjusted EPS growth target to 10%-14%. The filing does not state the prior target, so the size of the change relative to earlier guidance cannot be determined from this document alone.

  3. Why does the 2024 outlook matter for share count and dividends?

    The per-share outlook includes the expected effect of future share repurchases and anticipated 2024 dividends. Actual per-share results will therefore depend on how many shares are repurchased and the timing of those buybacks, which the filing says depends on price, market conditions, and alternative uses of capital.

  4. Are the new Evernorth product announcements material to financial results?

    The filing does not quantify any financial impact from EncircleRx, the Evernorth Behavioral Care Group, or the Humira biosimilar offering. They are strategic initiatives, and investors would need later disclosures to assess their contribution to revenue or earnings.

  5. Is the information in this 8-K legally considered filed?

    No. The filing states that the 8-K, including Exhibit 99.1, is furnished under Regulation FD and is not deemed filed for purposes of Section 18 of the Exchange Act. It also will not be incorporated by reference into other filings unless expressly stated in those filings.

04—Continue

← View all 8-K filings